TLDR The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
The document from 2015 presents a collection of research abstracts from the ESGCT and FSGT Collaborative Congress, showcasing advancements in gene therapy and cell transplantation. Notable findings include the potential of non-viral gene delivery systems, such as nanoparticles for androgenic alopecia treatment, and the use of gene therapy for various diseases, including muscular dystrophies and diabetes. Studies also explored the efficacy of novel gene delivery vectors, the therapeutic potential of modified cells, and the development of safer gene therapy methods. The research primarily involved animal models and cellular research, with no specific mention of the number of human participants.
7 citations,
August 2022 in “Journal of Nanobiotechnology” Advancements in nanoformulations for CRISPR-Cas9 genome editing can respond to specific triggers for controlled gene editing, showing promise in treating incurable diseases, but challenges like precision and system design complexity still need to be addressed.
51 citations,
June 2021 in “Signal Transduction and Targeted Therapy” The document concludes that while there are promising methods to control CRISPR/Cas9 gene editing, more research is needed to overcome challenges related to safety and effectiveness for clinical use.
2 citations,
March 2020 in “International Journal of Molecular Sciences” Topical treatments can deliver active molecules to skin stem cells, potentially helping treat skin and hair disorders, including skin cancers and hair loss.
November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
February 2024 in “International Journal For Multidisciplinary Research” Nanostructured lipid carriers are effective for treating hyperpigmentation in women aged 30-40.
